脓毒症相关急性肾损伤的体外血液净化治疗:SIAARTI-SIN联合委员会专家意见
脓毒症相关急性肾损伤是重症监护病房患者高发病率和高死亡率的危重病症。过去几十年发展了多种用于脓毒症及其相关急性肾损伤的体外血液净化治疗,但何时启动治疗及如何定义疗效仍不明确。SIAARTI与SIN联合委员会针对肾脏替代治疗在脓毒症与非脓毒症急性肾损伤中的适应证和时机、脓毒症相关急性肾损伤的最佳透析剂量、无急性肾损伤脓毒症患者使用体外血液净化的依据,以及吸附装置对特定介质清除和抗生素清除等问题提出临床实践建议,并制定该领域未来临床研究的共同框架。
要点
- 脓毒症相关急性肾损伤是ICU患者高发病率和高死亡率的危重病症。
- 体外血液净化治疗在临床实践中广泛使用,但启动时机和治疗疗效的定义仍不明确。
- 肾脏替代治疗在脓毒症与非脓毒症急性肾损伤患者中的适应证和时机仍存未解决问题。
- 脓毒症相关急性肾损伤患者肾脏替代治疗模式的最佳透析剂量尚待明确。
- 无急性肾损伤的脓毒症患者使用体外血液净化的依据、吸附装置对特定介质的清除及抗生素清除受到关注。
适用人群与场景
- 重症监护病房收治的脓毒症相关急性肾损伤危重患者。
研究设计与关键结果
- SIAARTI与SIN联合委员会针对脓毒症相关急性肾损伤的体外血液净化治疗提出临床实践建议,并制定该领域未来临床研究的共同框架。
证据类型、等级与局限
- 证据类型:SIAARTI-SIN联合委员会专家意见。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文未据此给出推荐。
指南或共识出处
- SIAARTI-SIN联合委员会专家意见(J Nephrol)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Sepsis-Associated Acute Kidney Injury is a life-threatening condition leading to high morbidity and mortality in critically ill patients admitted to the intensive care unit. Over the past decades, several extracorporeal blood purification therapies have been developed for both sepsis and sepsis-associated acute kidney injury management. Despite the widespread use of extracorporeal blood purification therapies in clinical practice, it is still unclear when to start this kind of treatment and how to define its efficacy. Indeed, several questions on sepsis-associated acute kidney injury and extracorporeal blood purification therapy still remain unresolved, including the indications and timing of renal replacement therapy in patients with septic vs. non-septic acute kidney injury, the optimal dialysis dose for renal replacement therapy modalities in sepsis-associated acute kidney injury patients, and the rationale for using extracorporeal blood purification therapies in septic patients without acute kidney injury. Moreover, the development of novel extracorporeal blood purification therapies, including those based on the use of adsorption devices, raised the attention of the scientific community both on the clearance of specific mediators released by microorganisms and by injured cells and potentially involved in the pathogenic mechanisms of organ dysfunction including sepsis-associated acute kidney injury, and on antibiotic removal. Based on these considerations, the joint commission of the Italian Society of Anesthesiology and Critical Care (SIAARTI) and the Italian Society of Nephrology (SIN) herein addressed some of these issues, proposed some recommendations for clinical practice and developed a common framework for future clinical research in this field.
参考来源
- De Rosa S, Marengo M, Fiorentino M, et al. Extracorporeal blood purification therapies for sepsis-associated acute kidney injury in critically ill patients: expert opinion from the SIAARTI-SIN joint commission. J Nephrol. 2023. PMID: 37439963. doi:10.1007/s40620-023-01637-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。